M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Valeant Pharmaceuticals International Inc's board reports launch of new USD1.5bn securities repurchase plan
The board of directors of Valeant Pharmaceuticals International Inc (NYSE:VRX)(TSX:VRX), a pharmaceutical company, said on Wednesday that it has approved up to USD1.5bn under its new securities repurchase programme.
As part of the securities repurchase plan, the company may make purchases...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives